Effect of dual inhibition of histone deacetylase and phosphatidylinositol-3 kinase in Philadelphia chromosome-positive leukemia cells

Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia

(2019) Xinyu Li et al.   HAEMATOLOGICA

HDAC1,2 Knock-Out and HDACi Induced Cell Apoptosis in Imatinib-Resistant K562 Cells

(2019) Shu-Huey Chen et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Epigenetic polypharmacology: A new frontier for epi-drug discovery

(2019) Daniela Tomaselli et al.   MEDICINAL RESEARCH REVIEWS

Dual HDAC and PI3K Inhibition Abrogates NFκB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas

(2018) Sharmistha Pal et al.   CANCER RESEARCH

Targeting the PI3K pathway in cancer: are we making headway?

(2018) Filip Janku et al.   Nature Reviews Clinical Oncology

Therapeutic targeting of Aurora A kinase in Philadelphia chromosome-positive ABL tyrosine kinase inhibitor-resistant cells

(2018) Seiichi Okabe et al.   Oncotarget

Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation

(2018) Seiichi Okabe et al.   ANNALS OF HEMATOLOGY

CUDC-907 blocks multiple pro-survival signals and abrogates microenvironment protection in CLL

(2018) Yixiang Chen et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma

(2018) Hui Guo et al.   ONCOGENE

CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial

(2017) Yasuhiro Oki et al.   HAEMATOLOGICA

Emerging therapies for acute myeloid leukemia

(2017) Caner Saygin et al.   Journal of Hematology & Oncology

Acetylation and deacetylation in cancer stem-like cells

(2017) Na Liu et al.   Oncotarget

CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial

(2017) Yasuhiro Oki et al.   HAEMATOLOGICA

Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial

(2016) Anas Younes et al.   LANCET ONCOLOGY

The Phosphatidylinositol 3-kinase/AKT/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients

(2015)   Oncotarget

Activity of omacetaxine mepesuccinate against ponatinib-resistant BCR-ABL-positive cells

(2013) S. Okabe et al.   BLOOD

Targeting survival pathways in chronic myeloid leukaemia stem cells

(2013) A Sinclair et al.   BRITISH JOURNAL OF PHARMACOLOGY

Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line

(2011) Seiichi Okabe et al.   Journal of Hematology & Oncology

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

(2010) Amie S. Corbin et al.   JOURNAL OF CLINICAL INVESTIGATION

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

(2009) Thomas O'Hare et al.   CANCER CELL